Nomenclature: M1 receptor

Family: Acetylcholine receptors (muscarinic)

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates. 

Contents

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 460 11q13 CHRM1 cholinergic receptor, muscarinic 1 11,78
Mouse 7 460 19 A Chrm1 cholinergic receptor, muscarinic 1, CNS 67,88
Rat 7 460 1q43-q51 Chrm1 cholinergic receptor, muscarinic 1 49,76,93,99
Previous and Unofficial Names
m1
acetylcholine receptor, muscarinic 1
Cholinergic receptor muscarin 1
Cholinergic receptor, muscarin 1
M1 muscarinic acetylcholine receptor
cholinergic receptor, muscarinic 1
m1 muscarinic acetylcholine receptor protein
muscarinic acetylcholine receptor M1
muscarinic acetylcholine receptor 1
Chrm-1
M1R
AW495047
Database Links
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
GPCRDB
GeneCards
GenitoUrinary Development Molecular Anatomy Project
HomoloGene
Human Protein Reference Database
InterPro
KEGG Gene
OMIM
PharmGKB Gene
PhosphoSitePlus
Protein Ontology (PRO)
RefSeq Nucleotide
RefSeq Protein
TreeFam
UniGene Hs.
UniProtKB
Wikipedia
Natural/Endogenous Ligands
acetylcholine
Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
NNC 11-1585 Hs Full agonist 9.9 pKi 20
pKi 9.9 [20]
pentylthio-TZTP Hs Full agonist 8.6 pKi 44
pKi 8.6 [44]
NNC 11-1607 Hs Full agonist 8.6 pKi 20
pKi 8.6 [20]
NNC 11-1314 Hs Full agonist 7.4 pKi 20
pKi 7.4 [20]
xanomeline Hs Partial agonist 6.7 – 7.9 pKi 21,45,106,116
pKi 6.7 – 7.9 [21,45,106,116]
sabcomeline Hs Partial agonist 6.7 pKi 116
pKi 6.7 [116]
arecaidine propargyl ester Hs Full agonist 6.4 pKi 44
pKi 6.4 [44]
AC-42 Hs Full agonist 6.2 pKi 53
pKi 6.2 [53]
oxotremorine Rn Partial agonist 6.0 pKi 69
pKi 6.0 [69]
arecoline Hs Full agonist 5.7 pKi 44
pKi 5.7 [44]
oxotremorine-M Rn Full agonist 5.6 pKi 69
pKi 5.6 [69]
oxotremorine Hs Partial agonist 5.5 pKi 44
pKi 5.5 [44]
arecoline Rn Partial agonist 5.3 pKi 69
pKi 5.3 [69]
pilocarpine Hs Partial agonist 5.1 pKi 44
pKi 5.1 [44]
oxotremorine-M Hs Full agonist 5.1 pKi 44
pKi 5.1 [44]
McN-A-343 Rn Partial agonist 5.1 pKi 69
pKi 5.1 [69]
acetylcholine Rn Full agonist 5.0 pKi 19
pKi 5.0 [19]
McN-A-343 Hs Partial agonist 4.8 – 5.2 pKi 84
pKi 4.8 – 5.2 [84]
pilocarpine Rn Partial agonist 4.9 pKi 69
pKi 4.9 [69]
milameline Hs Partial agonist 4.8 pKi 116
pKi 4.8 [116]
acetylcholine Hs Full agonist 4.3 – 4.9 pKi 44,55
pKi 4.3 – 4.9 [44,55]
methylfurmethide Hs Full agonist 4.6 pKi 44
pKi 4.6 [44]
(-)-YM796 Hs Partial agonist 4.3 – 4.8 pKi 108
pKi 4.3 – 4.8 [108]
(±)YM796 Hs Partial agonist 4.1 – 4.7 pKi 108
pKi 4.1 – 4.7 [108]
carbachol Hs Full agonist 3.2 – 5.3 pKi 21,44,116
pKi 3.2 – 5.3 [21,44,116]
furmethide Hs Full agonist 4.1 pKi 44
pKi 4.1 [44]
bethanechol Hs Full agonist 4.0 pKi 44
pKi 4.0 [44]
carbachol Rn Full agonist 3.9 pKi 19
pKi 3.9 [19]
bethanechol Rn Full agonist 3.7 pKi 69
pKi 3.7 [69]
methacholine Rn Agonist 6.4 pEC50 75
pEC50 6.4 (EC50 4x10-7 M) [75]
(+)-aceclidine Hs Full agonist 5.4 pEC50 26
pEC50 5.4 [26]
(-)-aceclidine Hs Partial agonist 5.0 pEC50 26
pEC50 5.0 [26]
View species-specific agonist tables
Agonist Comments
Please consult references [14,57,84,104,113] for further details of the activity of some of the ligands in this list.
Pilocarpine has been found to be a partial agonist [57,84,113] as well as a full agonist [104] at the M1 receptor.
Oxotremorine has been found to be a partial agonist [57,84,104] as well as a full agonist [84] at the M1 receptor.
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]QNB Hs Antagonist 10.6 – 10.8 pKd 22,78
pKd 10.6 – 10.8 (Kd 1.58x10-11 – 2.51x10-11 M) [22,78]
[3H]N-methyl scopolamine Rn Antagonist 9.7 pKd 19,104
pKd 9.7 [19,104]
[3H]N-methyl scopolamine Hs Antagonist 8.8 – 10.3 pKd 18,21-22,41,44-46,48,55
pKd 8.8 – 10.3 (Kd 5.01x10-11 – 1.58x10-9 M) [18,21-22,41,44-46,48,55]
biperiden Hs Antagonist 9.32 pKd 10
pKd 9.32 (Kd 4.8x10-10 M) [10]
[3H]darifenacin Hs Antagonist 8.8 pKd 91
pKd 8.8 [91]
[3H]pirenzepine Hs Antagonist 7.9 pKd 107
pKd 7.9 (Kd 1.4x10-8 M) [107]
MT7 Hs Antagonist 11.0 – 11.1 pKi 73
pKi 11.0 – 11.1 [73]
N-methyl scopolamine Hs Antagonist 9.9 pKi 29
pKi 9.9 [29]
umeclidinium Hs Antagonist 9.8 pKi 51
pKi 9.8 (Ki 1.6x10-10 M) [51]
propantheline Hs Antagonist 9.7 pKi 43
pKi 9.7 [43]
atropine Rn Antagonist 9.0 – 9.7 pKi 15,19,47
pKi 9.0 – 9.7 [15,19,47]
ipratropium Hs Antagonist 9.3 pKi 41
pKi 9.3 [41]
4-DAMP Hs Antagonist 9.2 pKi 25
pKi 9.2 [25]
dicyclomine Hs Antagonist 9.08 pKi 3
pKi 9.08 (Ki 8.3x10-10 M) [3]
atropine Hs Antagonist 8.5 – 9.6 pKi 21,29,41,43,78,91
pKi 8.5 – 9.6 [21,29,41,43,78,91]
scopolamine Hs Antagonist 9.0 pKi 43
pKi 9.0 [43]
4-DAMP Rn Antagonist 8.9 pKi 47
pKi 8.9 [47]
trihexyphenidyl Hs Antagonist 8.87 pKi 4
pKi 8.87 (Ki 1.35x10-9 M) [4]
tripitramine Hs Antagonist 8.8 pKi 64
pKi 8.8 [64]
silahexocyclium Rn Antagonist 8.7 pKi 15
pKi 8.7 [15]
oxybutynin Hs Antagonist 8.62 pKi 24
pKi 8.62 (Ki 2.4x10-9 M) [24]
hexocyclium Rn Antagonist 8.6 pKi 15
pKi 8.6 [15]
ethopropazine Rn Antagonist 8.51 pKi 16
pKi 8.51 (Ki 3.1x10-9 M) [16]
Description: Displacement of [H]QNB binding in rat forebrain brain homogenate.
darifenacin Hs Antagonist 8.3 pKi 41
pKi 8.3 [41]
hexahydrodifenidol Rn Antagonist 8.0 pKi 15
pKi 8.0 [15]
pirenzepine Rn Antagonist 7.8 – 7.9 pKi 15,47
pKi 7.8 – 7.9 [15,47]
methoctramine Rn Antagonist 7.8 pKi 15
pKi 7.8 [15]
VU0255035 Hs Antagonist 7.8 pKi 89
pKi 7.8 (Ki 1.487x10-8 M) [89]
HHSiD Hs Antagonist 7.7 pKi 27
pKi 7.7 [27]
HHSiD Rn Antagonist 7.4 – 7.9 pKi 15,47
pKi 7.4 – 7.9 [15,47]
AFDX384 Hs Antagonist 7.5 pKi 25
pKi 7.5 [25]
MT1 Hs Antagonist 7.3 – 7.6 pKi 29,38
pKi 7.3 – 7.6 [29,38]
guanylpirenzepine Rn Antagonist 7.3 – 7.6 pKi 1,103
pKi 7.3 – 7.6 [1,103]
p-F-HHSiD Hs Antagonist 7.1 – 7.8 pKi 27,43
pKi 7.1 – 7.8 [27,43]
pirenzepine Hs Antagonist 6.3 – 8.3 pKi 27,43,46,78
pKi 6.3 – 8.3 [27,43,46,78]
methoctramine Hs Antagonist 7.0 – 7.3 pKi 27,91
pKi 7.0 – 7.3 [27,91]
himbacine Hs Antagonist 6.7 – 7.1 pKi 46,71
pKi 6.7 – 7.1 [46,71]
MT3 Hs Antagonist 6.5 – 7.1 pKi 46
pKi 6.5 – 7.1 [46]
MT2 Hs Antagonist 6.4 pKi 38
pKi 6.4 [38]
otenzepad Hs Antagonist 6.2 pKi 27
pKi 6.2 [27]
otenzepad Rn Antagonist 5.9 – 6.3 pKi 15,47
pKi 5.9 – 6.3 [15,47]
lithocholylcholine Rn Antagonist 5.6 pKi 19
pKi 5.6 [19]
glycopyrrolate Hs Antagonist 9.9 pIC50 94
pIC50 9.9 (IC50 1.26x10-10 M) [94]
Description: Assay uses glycopyrronium bromide
aclidinium Hs Antagonist 9.85 pIC50 81
pIC50 9.85 (IC50 1.4x10-10 M) [81]
Description: Human M1 receptors expressed in CHO-K1 cells
solifenacin Hs Antagonist 7.2 pIC50 80
pIC50 7.2 (IC50 6.35x10-8 M) [80]
View species-specific antagonist tables
Antagonist Comments
Recombinant MT7 (rMT7) is often used for bioassays due to the limited availability of the M1 muscarinic receptor-selective mamba toxin MT7 or m1-toxin 1 (rMT7 has comparable affinity for M1[73]).

Biperiden is an approved drug antagonist of muscarinic acetylcholine receptors. We have tagged the M1 subtype as the drug's primary target as affinity is 10-fold higher at this receptor subtype [10]. Ethopropazine appears to have highest affinity for the M1 subtype in rat brain homegenates [16], so the M1 receptor is the likely primary human target of this drug.
Allosteric Modulators
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
KT 5720 Hs Positive 6.4 pKd 59
pKd 6.4 [59]
staurosporine Hs Positive 5.9 pKd 59
pKd 5.9 [59]
Gö 7874 Hs Negative 5.8 pKd 59
pKd 5.8 [59]
WIN 51,708 Hs Negative 5.8 pKd 60
pKd 5.8 [60]
KT 5823 Hs Positive 5.7 pKd 59
pKd 5.7 [59]
WIN 62,577 Hs Negative 5.5 pKd 60
pKd 5.5 [60]
brucine Hs Positive 4.5 – 5.7 pKd 44,58
pKd 4.5 – 5.7 [44,58]
K-252a Hs Positive 5.1 pKd 59
pKd 5.1 [59]
eburnamonine Hs Neutral 5.1 pKd 44
pKd 5.1 [44]
alcuronium Hs Negative 5.0 pKd 44
pKd 5.0 [44]
strychnine Hs Neutral 4.9 – 5.0 pKd 44,55
pKd 4.9 – 5.0 [44,55]
strychnine Hs Negative 4.9 pKd 55
pKd 4.9 [55]
vincamine Hs Neutral 4.8 pKd 44
pKd 4.8 [44]
brucine Hs Neutral 4.5 pKd 58
pKd 4.5 [58]
N-benzyl brucine Hs Negative 4.4 pKd 58
pKd 4.4 [58]
N-chloromethyl-brucine Hs Negative 4.1 pKd 58
pKd 4.1 [58]
thiochrome Hs Neutral 4.1 pKd 56
pKd 4.1 [56]
brucine N-oxide Hs Neutral 3.2 pKd 58
pKd 3.2 [58]
brucine N-oxide Hs Positive 3.2 pKd 58
pKd 3.2 [58]
AC-42 Hs Negative 6.2 pKi 53
pKi 6.2 [53]
clozapine Hs Positive 7.9 pIC50 96
pIC50 7.9 [96]
clozapine Rn Positive 7.7 pIC50 92
pIC50 7.7 [92]
N-desmethylclozapine Hs Positive 7.3 pIC50 96
pIC50 7.3 [96]
N-desmethylclozapine Rn Positive 6.8 pIC50 92
pIC50 6.8 [92]
AC-260584 Rn Positive 5.9 pIC50 92
pIC50 5.9 [92]
KT 5720 Hs Positive - - 8
[8]
brucine Hs Positive - - 8
[8]
VU0090157 Hs Positive - - 66
[66]
ML169 Hs Positive - - 83
[83]
BQCA Hs Positive - - 63
[63]
VU0029767 Hs Positive - - 66
[66]
View species-specific allosteric modulator tables
Primary Transduction Mechanisms
Transducer Effector/Response
Gq/G11 family Phospholipase C stimulation
References:  7,13,77,86
Tissue Distribution
Bladder.
Species:  Human
Technique:  RT-PCR.
References:  100
CNS: cerebral cortex, basal ganglia, limbic areas.
Species:  Human
Technique:  Radioligand binding.
References:  23
Vestibular system.
Species:  Human
Technique:  RT-PCR.
References:  102
Esophageal smooth muscle.
Species:  Human
Technique:  Radioligand binding.
References:  82
CNS: forebrain.
Species:  Mouse
Technique:  immunocytochemistry.
References:  42
CNS: cerbral cortex, corpus striatum, hippocampus, thalamus.
Species:  Mouse
Technique:  Radioligand binding.
References:  74
CNS: caudate putamen, nucleus accumbens, olfactory tubercle.
Species:  Rat
Technique:  in situ hybridisation.
References:  109
CNS: hippocampus.
Species:  Rat
Technique:  immunocytochemistry.
References:  61
CNS: pons.
Species:  Rat
Technique:  Radioligand binding.
References:  5
Heart: intrinsic neurons.
Species:  Rat
Technique:  in situ hybridisation.
References:  39
Vestibular system.
Species:  Rat
Technique:  RT-PCR.
References:  102
CNS: cranial nerve nuclei.
Species:  Rat
Technique:  in situ hybridisation.
References:  101
CNS: cerebral cortex, hippocampus, corpus striatum, olfactory tubercle, midbrain, pons-medulla, cerebellum.
Species:  Rat
Technique:  Immunoprecipitation.
References:  118
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of PI levels in mouse Y1 adrenal cells transfected with the mouse M1 receptor.
Species:  Mouse
Tissue:  Y1 adrenal cells.
Response measured:  Stimulation of PI hydrolysis.
References:  88
Measurement of PI hydrolysis, Ca2+ mobilisation and [3H]arachidonic acid release in A9 L cells transfected with the human M1 receptor.
Species:  Human
Tissue:  A9 L cells.
Response measured:  Stimulation of PI hydrolysis, Ca2+ mobilisation and [3H]arachidonic acid release.
References:  6
Measurement of PI hydrolysis in CHO cells transfected with the human M1 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Stimulation of PI hydrolysis.
References:  20
Measurement of ERK1/2 activity in hippocampal cells endogenously expressing the M1 receptor.
Species:  Rat
Tissue:  Post-ischemic hippocampus.
Response measured:  Increase in ERK1/2 activity.
References:  98
Measurement of activation of ERK1/2 in PC12D cells endogeneously expressing the M1 receptor.
Species:  Rat
Tissue:  Neuronal PC12D cells.
Response measured:  Activation of ERK1/2.
References:  34
Measurement of activation of neuronal nitric oxide synthetase in chinese hamster overy cells transfected with the M1 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Activation of nitric oxide synthetase.
References:  105
Measurement of ERK1/2 activity in COS-7 cells transfected with the human M2 receptor.
Species:  Human
Tissue:  COS-7 cells.
Response measured:  Increase in ERK1/2 activity.
References:  85
Measurement of GIRK channel activity in Xenopus oocytes transfected with the human M1 receptor.
Species:  Human
Tissue:  Xenopus oocytes.
Response measured:  Inhibition of GIRK channels.
References:  40
Measurement of the effects of a ligand on the level, or rate, of binding of GTPγ35S to membranes.
Species:  Human
Tissue:  CHO cell membranes.
Response measured:  The binding of GTPγ35S to G proteins coupled to the receptor.
References:  9,54-57,59-60
Measurement of the effects of a ligand on the rate of hydrolysis of GTP by G proteins in membranes.
Species:  Human
Tissue:  CHO cells.
Response measured:  Generation of 32Pi from [γ-32P]GTP.
References:  57
Physiological Functions
Stimulation of urination.
Species:  Rat
Tissue:  In vivo.
References:  50
Bronchoconstriction.
Species:  Human
Tissue:  In vivo.
References:  52
Vasodilation.
Species:  Rat
Tissue:  Lung.
References:  114
Modulation of NMDA receptor-meditated excitatory synaptic transmission.
Species:  Rat
Tissue:  Hippocampal CA1 pyramidal cells.
References:  65
Regulation of circadian rhythms.
Species:  Rat
Tissue:  Hypothalamic suprachiasmatic nucleus.
References:  33
Automaticity of the heart.
Species:  Mouse
Tissue:  Heart.
References:  115
Autoreceptor: modulation of ACh release.
Species:  Rat
Tissue:  Basal forebrain slices.
References:  97
Autoreceptor: modulation of ACh release.
Species:  Human
Tissue:  Neocortex slices.
References:  28
Stimulation of water consumption.
Species:  Rat
Tissue:  In vivo.
References:  79
Hypothermia.
Species:  Rat
Tissue:  In vivo.
References:  87
Spinal analgesia.
Species:  Rat
Tissue:  In vivo.
References:  32
Memory function.
Species:  Rat
Tissue:  In vivo.
References:  70
Physiological Consequences of Altering Gene Expression
M1 receptor knockout mice exhibit reduced seizure activity in the pilocarpine model of epilepsy.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  37
M1 receptor knockout mice exhibit loss of regulation of M-current potassium channel activity.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  37
M1 receptor knockout mice exhibit a loss of the positive chronotropic and inotropic responses.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  36
M1 receptor knockout mice exhibit increased locomotor activity and hyperactivity under stress.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  72
M1 receptor knockout mice exhibit increased dopamine levels in the striatum and increased locomotor activity.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  31
M1 receptor knockout mice showed normal or even enhanced memory for tasks that involve matching-to-sample problems but significant impairments in non-matching-to-sample working memory and consolidation.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  2
M1 receptor knockout mice exhibit reduced salivary flow.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  30
M1 receptor knockout mice exhibit disrupted tonotopic organisation and frequency tuning in the auditory cortex.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  119-120
M1 receptor knockout mice exhibit reduced gastric pepsinogen secretion.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  117
Hippocampal slices from M1 receptor knockout mice do not exhibit carbachol-induced enhancement of LTP of excitatory synaptic transmission as seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  90
M1 receptor knockout mice exhibit reduced carbachol-stimulated ion secretion in the colon compared to wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  35
Lung slices from M1 receptor knockout mice exhibit increased agonist-induced bronchoconstriction compared to wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  95
M1 receptor knockout mice exhibit an increased tidal volume of the lung at rest.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  12
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Chrm1tm1Nmn Chrm1tm1Nmn/Chrm1tm1Nmn
B6.129X1-Chrm1
MGI:88396  MP:0004631 abnormal auditory cortex morphology PMID: 15721569 
Chrm1tm1Nmn Chrm1tm1Nmn/Chrm1tm1Nmn
B6.129X1-Chrm1
MGI:88396  MP:0004788 abnormal auditory cortex tonotopy PMID: 15721569 
Chrm1tm1Nmn Chrm1tm1Nmn/Chrm1tm1Nmn
B6.129X1-Chrm1
MGI:88396  MP:0004996 abnormal CNS synapse formation PMID: 15721569 
Chrm1tm1Jwe|Chrm4tm1Jwe Chrm1tm1Jwe/Chrm1tm1Jwe,Chrm4tm1Jwe/Chrm4tm1Jwe
involves: 129S6/SvEvTac * CF-1
MGI:88396  MGI:88399  MP:0002206 abnormal CNS synaptic transmission PMID: 15919709 
Chrm1tm2.1Stl|Emx1tm1.1(cre)Ito Chrm1tm2.1Stl/Chrm1tm2.1Stl,Emx1tm1.1(cre)Ito/0
involves: 129P2/OlaHsd
MGI:88396  MGI:95387  MP:0002910 abnormal excitatory postsynaptic currents PMID: 20080609 
Chrm1tm2.1Stl|Tg(Grik4-cre)G32-4Stl Chrm1tm2.1Stl/Chrm1tm2.1Stl,Tg(Grik4-cre)G32-4Stl/0
involves: 129P2/OlaHsd * C57BL/6
MGI:2448783  MGI:88396  MP:0002910 abnormal excitatory postsynaptic currents PMID: 20080609 
Chrm1tm1Stl Chrm1tm1Stl/Chrm1tm1Stl
involves: C57BL/6
MGI:88396  MP:0002912 abnormal excitatory postsynaptic potential PMID: 16290192 
Chrm1tm1Kano Chrm1tm1Kano/Chrm1tm1Kano
involves: 129X1/SvJ * C57BL/6
MGI:88396  MP:0002945 abnormal inhibitory postsynaptic currents PMID: 12859343 
Chrm1tm1Kano|Chrm3tm1Mmt Chrm1tm1Kano/Chrm1tm1Kano,Chrm3tm1Mmt/Chrm3tm1Mmt
involves: 129X1/SvJ * C57BL/6
MGI:88396  MGI:88398  MP:0002945 abnormal inhibitory postsynaptic currents PMID: 12859343 
Chrm1tm2.1Stl|Emx1tm1.1(cre)Ito Chrm1tm2.1Stl/Chrm1tm2.1Stl,Emx1tm1.1(cre)Ito/0
involves: 129P2/OlaHsd
MGI:88396  MGI:95387  MP:0001898 abnormal long term depression PMID: 20080609 
Chrm1tm2.1Stl|Tg(Grik4-cre)G32-4Stl Chrm1tm2.1Stl/Chrm1tm2.1Stl,Tg(Grik4-cre)G32-4Stl/0
involves: 129P2/OlaHsd * C57BL/6
MGI:2448783  MGI:88396  MP:0001898 abnormal long term depression PMID: 20080609 
Chrm1tm2.1Stl|Emx1tm1.1(cre)Ito Chrm1tm2.1Stl/Chrm1tm2.1Stl,Emx1tm1.1(cre)Ito/0
involves: 129P2/OlaHsd
MGI:88396  MGI:95387  MP:0004753 abnormal miniature excitatory postsynaptic currents PMID: